Nurix Therapeutics (NRIX) Net Cash Flow Growth (3y) (2022 - 2026)

Nurix Therapeutics (NRIX) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -50.33%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.47%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 33.37%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -29.82%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Nurix Therapeutics 2.64 Bn 2.19 Bn - -28.83%

Historic Data

Download Data
DateValue
May 31, 2026 -28.83%
Feb 28, 2026 -78.50%
Nov 30, 2025 115.16%
Aug 31, 2025 -43.51%
May 31, 2025 30.53%
Feb 28, 2025 -213.04%
Nov 30, 2024 29.34%
Aug 31, 2024 24.14%
May 31, 2024 2.70%
Feb 29, 2024 -38.99%
Nov 30, 2023 27.74%
Aug 31, 2023 -29.20%
May 31, 2023 -37.28%
Feb 28, 2023 -50.83%
Nov 30, 2022 44.12%